|
KMID : 0606920210290030268
|
|
Biomolecules & Therapeutics
2021 Volume.29 No. 3 p.268 ~ p.272
|
|
|
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
|
|
Bae Joon-Yong
Lee Gee-Eun
Park Hee-Do
Cho Ju-Young
Kim Jeong-Hun
Lee Jung-Min
Kim Ki-Soon
Kim Jin-Il
Park Man-Seong
|
|
|
Abstract
|
|
|
|
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
|
|
|
KEYWORD
|
|
|
Antiviral, COVID-19, Drug repurposing, SARS-CoV-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|